12/21/2023 0 Comments Elucidate inc![]() The round led by Frontline Ventures with participation from existing investors Seed X Liechtenstein, APEX Ventures, and Big Start Ventures. Manuals - Cat# - Cell line - Reporter Pathway - Qty 3-4 x10^6 EL-NFKBRAW - eLUCidate RAW 264.7 - NF-kB EL-IL8RAW - eLUCidate RAW 264.7 - IL-8 EL-AP1293 - eLUCidate HEK 293 - AP-1 EL-MIP2293 - eLUCidate HEK 293 - MIP-2 EL-MIP2RAW - eLUCidate RAW 264.7 - MIP-2 EL-TNFA293 - eLUCidate HEK 293 - TNF-a EL-TNFARAW - eLUCidate RAW 264.7 - TNF-a EL-TNFB293 - eLUCidate HEK 293 - TNF-b EL-TNFBRAW - eLUCidate RAW 264.7 - TNF-b EL-GATA3293 - eLUCidate HEK 293 - GATA3 EL-NFAT293 - eLUCidate HEK 293 - NFAT EL-NFATRAW - eLUCidate RAW 264.7 - NFAT EL-STAT1HELA - eLUCidate HeLa - STAT1 EL-STAT1RAW - eLUCidate RAW 264.7 - STAT1 EL-STAT3293 - eLUCidate HEK 293 - STAT3 EL-INOSRAW - eLUCidate RAW 264.Elucidate, a Berlin, Germany-based financial crime risk scoring platform, raised €2.5m in pre-Series-A funding. Shipping/Storage: All eLUCidate cell lines are shipped on dry ice only, and storage recommended in liquid nitrogen onlyĬat# - Cell line - Reporter Pathway - Qty 3-4 x10^6ĮL-STAT1RAW - eLUCidate RAW 264.7 - STAT1ĮL-IFNB293 - eLUCidate HEK 293 - TLR3/IFNBĮL-ISRE293 - eLUCidate HEK 293 - TLR3/ISREĮL-TLR2293 - eLUCidate HEK 293 - TLR2/NF-kBĮL-TLR3293 - eLUCidate HEK 293 - TLR3/NF-kBĮL-TLR7293 - eLUCidate HEK 293 - TLR7/NF-kBĮL-TLR8293 - eLUCidate HEK 293 - TLR8/NF-kBĮL-TLR9293 - eLUCidate HEK 293 - TLR9/NF-kBĮL-CRE293 - eLUCidate HEK 293 - CRE Cat# - Cell line - Reporter Pathway - Qty 2-3 x10^6ĮL-TLR5293 - eLUCidate HEK 293 - TLR5/NF-kB The eLUCidate Reporter Cell Lines allow users to measure the potency and selectivity of compounds on key pathways, especially if used in a high throughput system. The variety of cell lines and transcriptional activators that Genlantis offers allows scientist to study the behaviors of multiple pathways of interest by monitoring luciferase activity after exposure to drug candidates or other stimuli. The eLUCidate Reporter Cell Lines have been constructed with an optimized and highly active luciferase reporter technology. Genlantis is pleased to offer a substantial collection of high quality Luciferase expressing reporter cell lines. Malfunctioning protein and/or signaling pathways are therefore very important in understanding the mechanism of a particular pathology, and may lead to the proper investigation of the cause of a disease, especially for cancer, and can also lead to possible targeted solutions. Having a clear knowledge of how a protein regulates signaling and metabolic pathways is a first step in disease research. Understanding the function of proteins in normal versus abnormal cellular environments is an important key to drug discovery processes. These signaling pathways are composed mainly of proteins that can interact, move to specific cellular locations, or be modified or degraded. Signal transduction pathways are the bridges that connect the extracellular environment cues, for example the binding by a specific cell surface receptor of a hormone, to the ensuing cellular response. Genlantis now offers a large collection of pathway reporter stable cell lines, all using a highly active luciferase reporter system. Stringent quality control - Each cell line is tested for performance and sterility.Optimized Luciferase reporter gene - High sensitivity and dynamic range.Highest number of cells per vial (3 x 10^6) - Cells are ready for use shortly after thawing.The eLUCidate Reporter Cell Lines offer the following features and benefits Lab Sterilization, Sanitation, and Decontamination.High-Throughput & Transfection Optimization.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |